We then analyzed the immune checkpoints (Figures 10C,D), we can see from the picture nearly every immune checkpoint has been revealed to be more active in the low-risk BC group, including CD274 (PDL1), LAG3, PDCD1 (PD1), TNFRSF18 and LGALS9, suggesting that these individuals may be more responsive to immunotherapy. The gene discussed is TNFRSF18; the disease is breast cancer.